Capra Biosciences Inc.

Capra Biosciences Inc. is a company focused on producing renewable chemicals using an artificial intelligence-powered innovative bioreactor technology platform, offering high-performance products such as retinol and hydrophobic lubricants, contributing to sustainable chemical solutions. Founded in 2020 and headquartered in Manassas, Virginia, Capra Biosciences Inc. was co-founded by Andrew Magyar and Elizabeth Onderko, CEO.

The company specializes in the production of renewable chemicals through advanced bioreactors. In August 2026, Capra Biosciences Inc. received grant funding from the U. S.

Department of Health and Human Services. Capra Biosciences specializes in the production of high-performance renewable chemicals through its innovative bioreactor technology. The company's primary offerings include retinol, a form of vitamin A used in anti-aging cosmetics, and various hydrophobic lubricants. These products are manufactured using biological processes that convert waste materials into valuable chemicals, aligning with sustainable practices.

The bioreactors employed by Capra utilize biofilms to facilitate the biosynthesis of these chemicals. Capra's products target industries focused on cosmetics and personal care, with an emphasis on providing environmentally friendly alternatives. Capra Biosciences generates revenue through direct sales of its chemical products to businesses within the cosmetics and personal care industries. The company engages in B2B transactions, supplying retinol and lubricants to manufacturers who incorporate these materials into their product lines.

Partnerships with retailers and wholesalers further facilitate distribution, enhancing product availability in the market. The pricing structure for Capra's offerings reflects their sustainable chemicals' premium nature, catering to clients seeking eco-friendly solutions. The company plans to use the August 2026 funding to advance domestic production of critical active pharmaceutical ingredients, support current good manufacturing practice production and regulatory filings, and expand development of additional pharmaceutical ingredient targets.